Picture of LeMaitre Vascular logo

LMAT — LeMaitre Vascular News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

LeMaitre Vascular Q3 sales slightly beat estimates on EMEA performance

LeMaitre Vascular Q3 sales slightly beat estimates on EMEA performance


Overview

  • U.S. vascular device maker's Q3 sales rose 11%, slightly beating analyst expectations

  • Company acquired B. Braun vascular assets, expanding product portfolio outside North America


Outlook

  • LeMaitre sees Q4 2026 sales of $69.9 mln to $71.9 mln

  • Company expects full-year 2026 sales of $274.8 mln to $276.8 mln

  • LeMaitre forecasts Q4 2026 EPS of $0.70 to $0.75 and full-year EPS of $2.77 to $2.82


Result Drivers

  • PRODUCT SEGMENTS - Grafts and shunts drove Q3 growth, with graft sales up 20% and shunt sales up 14%

  • PRICING AND VOLUME - Organic sales growth was driven by a 7% increase in average selling prices and a 5% rise in units sold

  • REGIONAL PERFORMANCE - EMEA sales increased 18%, Americas 9%, and APAC 5%


Company press release: ID:nGNX7lHlWx


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

$67.97 mln

$67.39 mln (8 Analysts)

Q3 Net Income

$15.02 mln

Q3 Gross Profit

$48.7 mln

Q3 Income From Operations

$17.7 mln

Q3 Pretax Profit

$19.67 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for LeMaitre Vascular, Inc. is $100.00, about 24.1% above its November 3 closing price of $80.60

  • The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 32 three months ago


Reuters Recommended Reads

  • Nov 2 - SI-BONE Q3 revenue rises 14.5%, slightly beats estimates

  • Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook

  • Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on LeMaitre Vascular

See all news